Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Self-amplifying mRNA vaccines.

Brito LA, Kommareddy S, Maione D, Uematsu Y, Giovani C, Berlanda Scorza F, Otten GR, Yu D, Mandl CW, Mason PW, Dormitzer PR, Ulmer JB, Geall AJ.

Adv Genet. 2015;89:179-233. doi: 10.1016/bs.adgen.2014.10.005. Epub 2014 Dec 4.

PMID:
25620012
2.

A cationic nanoemulsion for the delivery of next-generation RNA vaccines.

Brito LA, Chan M, Shaw CA, Hekele A, Carsillo T, Schaefer M, Archer J, Seubert A, Otten GR, Beard CW, Dey AK, Lilja A, Valiante NM, Mason PW, Mandl CW, Barnett SW, Dormitzer PR, Ulmer JB, Singh M, O'Hagan DT, Geall AJ.

Mol Ther. 2014 Dec;22(12):2118-29. doi: 10.1038/mt.2014.133. Epub 2014 Jul 16.

3.

Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.

Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, Otten GR, Brazzoli M, Buccato S, Bonci A, Casini D, Maione D, Qi ZQ, Gill JE, Caiazza NC, Urano J, Hubby B, Gao GF, Shu Y, De Gregorio E, Mandl CW, Mason PW, Settembre EC, Ulmer JB, Craig Venter J, Dormitzer PR, Rappuoli R, Geall AJ.

Emerg Microbes Infect. 2013 Aug;2(8):e52. doi: 10.1038/emi.2013.54. Epub 2013 Aug 14.

4.

Generation of a parvovirus B19 vaccine candidate.

Chandramouli S, Medina-Selby A, Coit D, Schaefer M, Spencer T, Brito LA, Zhang P, Otten G, Mandl CW, Mason PW, Dormitzer PR, Settembre EC.

Vaccine. 2013 Aug 20;31(37):3872-8. doi: 10.1016/j.vaccine.2013.06.062. Epub 2013 Jul 2.

PMID:
23827313
5.

RNA: the new revolution in nucleic acid vaccines.

Geall AJ, Mandl CW, Ulmer JB.

Semin Immunol. 2013 Apr;25(2):152-9. doi: 10.1016/j.smim.2013.05.001. Epub 2013 Jun 2. Review.

PMID:
23735226
6.

Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies.

Loomis RJ, Lilja AE, Monroe J, Balabanis KA, Brito LA, Palladino G, Franti M, Mandl CW, Barnett SW, Mason PW.

Vaccine. 2013 Jan 30;31(6):919-26. doi: 10.1016/j.vaccine.2012.12.009. Epub 2012 Dec 14.

PMID:
23246547
7.

Nonviral delivery of self-amplifying RNA vaccines.

Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T, O'Hagan DT, Singh M, Mason PW, Valiante NM, Dormitzer PR, Barnett SW, Rappuoli R, Ulmer JB, Mandl CW.

Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14604-9. doi: 10.1073/pnas.1209367109. Epub 2012 Aug 20.

8.

RNA-based vaccines.

Ulmer JB, Mason PW, Geall A, Mandl CW.

Vaccine. 2012 Jun 22;30(30):4414-8. doi: 10.1016/j.vaccine.2012.04.060. Epub 2012 Apr 28. Review.

PMID:
22546329
9.

The interface of animal and human vaccines.

Schmaljohn C, Mandl CW.

Curr Opin Virol. 2012 Jun;2(3):306-8. doi: 10.1016/j.coviro.2012.04.001. Epub 2012 Apr 26. No abstract available.

PMID:
22542098
10.

Generation and genetic stability of tick-borne encephalitis virus mutants dependent on processing by the foot-and-mouth disease virus 3C protease.

Schrauf S, Kurz M, Taucher C, Mandl CW, Skern T.

J Gen Virol. 2012 Mar;93(Pt 3):504-515. doi: 10.1099/vir.0.038398-0. Epub 2011 Nov 30.

11.

Vaccines for the twenty-first century society.

Rappuoli R, Mandl CW, Black S, De Gregorio E.

Nat Rev Immunol. 2011 Nov 4;11(12):865-72. doi: 10.1038/nri3085. Review. Erratum in: Nat Rev Immunol. 2012 Mar;12(3):225.

PMID:
22051890
12.

Mutational analysis of three predicted 5'-proximal stem-loop structures in the genome of tick-borne encephalitis virus indicates different roles in RNA replication and translation.

Rouha H, Hoenninger VM, Thurner C, Mandl CW.

Virology. 2011 Aug 15;417(1):79-86. doi: 10.1016/j.virol.2011.05.008. Epub 2011 Jun 8.

13.

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.

Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, Dormitzer PR, Carfi A.

Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9619-24. doi: 10.1073/pnas.1106536108. Epub 2011 May 17.

14.

Functional microRNA generated from a cytoplasmic RNA virus.

Rouha H, Thurner C, Mandl CW.

Nucleic Acids Res. 2010 Dec;38(22):8328-37. doi: 10.1093/nar/gkq681. Epub 2010 Aug 12.

15.

Mutations at positions 186 and 194 in the HA gene of the 2009 H1N1 pandemic influenza virus improve replication in cell culture and eggs.

Suphaphiphat P, Franti M, Hekele A, Lilja A, Spencer T, Settembre E, Palmer G, Crotta S, Tuccino AB, Keiner B, Trusheim H, Balabanis K, Sackal M, Rothfeder M, Mandl CW, Dormitzer PR, Mason PW.

Virol J. 2010 Jul 14;7:157. doi: 10.1186/1743-422X-7-157.

16.

Characterization of West Nile virus live vaccine candidates attenuated by capsid deletion mutations.

Schlick P, Kofler RM, Schittl B, Taucher C, Nagy E, Meinke A, Mandl CW.

Vaccine. 2010 Aug 16;28(36):5903-9. doi: 10.1016/j.vaccine.2010.06.045. Epub 2010 Jun 25.

PMID:
20600500
17.

A trans-complementing recombination trap demonstrates a low propensity of flaviviruses for intermolecular recombination.

Taucher C, Berger A, Mandl CW.

J Virol. 2010 Jan;84(1):599-611. doi: 10.1128/JVI.01063-09.

18.

Extension of flavivirus protein C differentially affects early RNA synthesis and growth in mammalian and arthropod host cells.

Schrauf S, Mandl CW, Bell-Sakyi L, Skern T.

J Virol. 2009 Nov;83(21):11201-10. doi: 10.1128/JVI.01025-09. Epub 2009 Aug 19.

19.

Antibody affinity maturation and respiratory syncytial virus disease.

Shaw CA, Otten G, Wack A, Palmer GA, Mandl CW, Mbow ML, Valiante N, Dormitzer PR.

Nat Med. 2009 Jul;15(7):725; author reply 725-6. doi: 10.1038/nm0709-725a. No abstract available.

PMID:
19584854
20.

Helices alpha2 and alpha3 of West Nile virus capsid protein are dispensable for assembly of infectious virions.

Schlick P, Taucher C, Schittl B, Tran JL, Kofler RM, Schueler W, von Gabain A, Meinke A, Mandl CW.

J Virol. 2009 Jun;83(11):5581-91. doi: 10.1128/JVI.02653-08. Epub 2009 Mar 18.

21.

Spatial and temporal organization of tick-borne encephalitis flavivirus replicated RNA in living cells.

Miorin L, Maiuri P, Hoenninger VM, Mandl CW, Marcello A.

Virology. 2008 Sep 15;379(1):64-77. doi: 10.1016/j.virol.2008.06.025. Epub 2008 Jul 29.

22.

Changing the protease specificity for activation of a flavivirus, tick-borne encephalitis virus.

Fischl W, Elshuber S, Schrauf S, Mandl CW.

J Virol. 2008 Sep;82(17):8272-82. doi: 10.1128/JVI.00587-08. Epub 2008 Jun 18.

23.

Analysis of the effects of alterations in the tick-borne encephalitis virus 3'-noncoding region on translation and RNA replication using reporter replicons.

Hoenninger VM, Rouha H, Orlinger KK, Miorin L, Marcello A, Kofler RM, Mandl CW.

Virology. 2008 Aug 1;377(2):419-30. doi: 10.1016/j.virol.2008.04.035. Epub 2008 Jun 3.

24.

Functional analysis of potential carboxy-terminal cleavage sites of tick-borne encephalitis virus capsid protein.

Schrauf S, Schlick P, Skern T, Mandl CW.

J Virol. 2008 Mar;82(5):2218-29. Epub 2007 Dec 26.

25.
26.
29.
30.
31.
33.
34.

Tick-borne virus diseases of human interest in Europe.

Charrel RN, Attoui H, Butenko AM, Clegg JC, Deubel V, Frolova TV, Gould EA, Gritsun TS, Heinz FX, Labuda M, Lashkevich VA, Loktev V, Lundkvist A, Lvov DV, Mandl CW, Niedrig M, Papa A, Petrov VS, Plyusnin A, Randolph S, Süss J, Zlobin VI, de Lamballerie X.

Clin Microbiol Infect. 2004 Dec;10(12):1040-55. Review.

35.
36.

A novel principle of attenuation for the development of new generation live flavivirus vaccines.

Kofler RM, Heinz FX, Mandl CW.

Arch Virol Suppl. 2004;(18):191-200. Review.

PMID:
15119774
37.

Mimicking live flavivirus immunization with a noninfectious RNA vaccine.

Kofler RM, Aberle JH, Aberle SW, Allison SL, Heinz FX, Mandl CW.

Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1951-6. Epub 2004 Feb 9.

38.

Two distinct size classes of immature and mature subviral particles from tick-borne encephalitis virus.

Allison SL, Tao YJ, O'Riordain G, Mandl CW, Harrison SC, Heinz FX.

J Virol. 2003 Nov;77(21):11357-66.

39.

Incorporation of tick-borne encephalitis virus replicons into virus-like particles by a packaging cell line.

Gehrke R, Ecker M, Aberle SW, Allison SL, Heinz FX, Mandl CW.

J Virol. 2003 Aug;77(16):8924-33.

40.

Role of heparan sulfate for attachment and entry of tick-borne encephalitis virus.

Kroschewski H, Allison SL, Heinz FX, Mandl CW.

Virology. 2003 Mar 30;308(1):92-100.

41.

Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus.

Elshuber S, Allison SL, Heinz FX, Mandl CW.

J Gen Virol. 2003 Jan;84(Pt 1):183-91.

PMID:
12533715
42.

Spontaneous mutations restore the viability of tick-borne encephalitis virus mutants with large deletions in protein C.

Kofler RM, Leitner A, O'Riordain G, Heinz FX, Mandl CW.

J Virol. 2003 Jan;77(1):443-51.

44.

Role of metastability and acidic pH in membrane fusion by tick-borne encephalitis virus.

Stiasny K, Allison SL, Mandl CW, Heinz FX.

J Virol. 2001 Aug;75(16):7392-8.

45.
46.

Mutational evidence for an internal fusion peptide in flavivirus envelope protein E.

Allison SL, Schalich J, Stiasny K, Mandl CW, Heinz FX.

J Virol. 2001 May;75(9):4268-75.

47.
48.

Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy.

Puchhammer-Stöckl E, Mandl CW, Kletzmayr J, Holzmann H, Hofmann A, Aberle SW, Heinz FX, Watschinger B, Hofmann H.

J Infect Dis. 2000 Jun;181(6):2063-6. Epub 2000 May 23.

PMID:
10837194
49.

A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms.

Aberle JH, Aberle SW, Allison SL, Stiasny K, Ecker M, Mandl CW, Berger R, Heinz FX.

J Immunol. 1999 Dec 15;163(12):6756-61.

50.

Reduced interferon-gamma expression in peripheral blood mononuclear cells of infants with severe respiratory syncytial virus disease.

Aberle JH, Aberle SW, Dworzak MN, Mandl CW, Rebhandl W, Vollnhofer G, Kundi M, Popow-Kraupp T.

Am J Respir Crit Care Med. 1999 Oct;160(4):1263-8.

PMID:
10508817

Supplemental Content

Loading ...
Support Center